These groups are thinking, quite rightly, in terms of todays patients and therapies. Why should drug companies be able to advertise successful results from one clinical trial while burying results from ones showing a drug has no effect?
But theres even more at stake. The registry could change the economics of drug development by making clinical trials, the most expensive aspect of drug development, cheaper.
The more patients in a clinical trial, the more it costs. But if you had the right kind of data from the registry, "you should be able to build better trials that require fewer patients," according to David Handelsman, lead strategist for clinical research and development at SAS Institute, a company that supplies statistical and modeling tools to analyze and design clinical trials.
Some of the most useful, and most secret, information is from trials showing the drug doesnt work, says Alex Bangs, CTO of Entelos. "If we assume that it would be nice to stop reinventing the wheel, then theres no doubt that having negative data would help," he said.
Entelos builds in silico models of physiological systems and uses them to help drug companies diagnose disease and predict drug response more efficiently. The company, along with Roche Diagnostics, recently won an award for developing a much less invasive form of a common diagnostic test for diabetes. To build these models, Entelos uses information from the peer-reviewed literature.
Much of the data out there comes from animals and cell cultures. These require "a lot of interpretation," he explained. But clinical data, by definition, comes from humans. "Anytime we can get that kind of data," he said, "we can use that as a validation of the model."